Response-guided Triple-therapy Using Boceprevir in Combination With PEGIFN/RBV in HIV/HCV-coinfected Patients

Trial Profile

Response-guided Triple-therapy Using Boceprevir in Combination With PEGIFN/RBV in HIV/HCV-coinfected Patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Mar 2017

At a glance

  • Drugs Boceprevir (Primary) ; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C; HIV infections
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 15 Dec 2016 Status changed from recruiting to completed.
    • 14 Sep 2013 New source identified and integrated (European Clinical Trials Database, 992366).
    • 21 Aug 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top